CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Valentina Boni, Howard A. Burris III, Joyce F. Liu, Alexander I. Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Lee S. Rosen, Randy F. Sweis, Nataliya Volodymyrivna Uboha, Rachel E. Sanborn, Bert O'Neil, James J. Harding, Patricia LoRusso, Amy M. Weise, Javier Garcia-Corbacho, Iván Victoria, John W. Frye, Rachel Li, Mark Stroh, Funda Meric-Bernstam
Institutions: Sarah Cannon, Dana-Farber Cancer Institute, Virginia Cancer Specialists, Sarah Cannon Research Institute, Rush University Medical Center, University of California, Los Angeles, UCLA Medical Center, University of Chicago, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Providence Portland Medical Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Yale University, The Barbara Ann Karmanos Cancer Institute, Hospital Clínic de Barcelona, CytomX Therapeutics (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032591595